-
1.
公开(公告)号:US20050130948A1
公开(公告)日:2005-06-16
申请号:US10507000
申请日:2003-03-27
申请人: Daryl Rees , Phil Gunning , Antonia Orsi , Zongqin Xia , Yaer Hu
发明人: Daryl Rees , Phil Gunning , Antonia Orsi , Zongqin Xia , Yaer Hu
IPC分类号: A61K31/58 , A61K31/585 , A61K31/655 , A61P9/02 , A61P9/04 , A61P11/06 , A61P21/00 , A61P21/04 , A61P25/08 , A61P25/16 , A61P25/28 , A61P27/00 , C07J20060101 , C07J71/00
CPC分类号: A61K31/58 , A61K31/655 , C07J71/00 , C07J71/0005 , Y02A50/465
摘要: The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.
摘要翻译: 本发明公开了某些甾体皂苷元,相关化合物及其衍生物在治疗非认知神经退行性疾病,非认知性神经肌肉变性,运动感觉神经变性或受体功能障碍或不存在认知神经和神经损伤的情况下的治疗方法和用途。 神经肌肉损伤
-
2.
公开(公告)号:US20110190249A1
公开(公告)日:2011-08-04
申请号:US13085225
申请日:2011-04-12
申请人: Daryl REES , Phil Gunning , Antonia Orsi , Zongqin Xia , Yaer Hu
发明人: Daryl REES , Phil Gunning , Antonia Orsi , Zongqin Xia , Yaer Hu
CPC分类号: A61K31/655 , A61K31/58 , C07J71/0005 , Y02A50/465
摘要: The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.
摘要翻译: 本发明公开了某些甾体皂苷元,相关化合物及其衍生物在治疗非认知神经退行性疾病,非认知性神经肌肉变性,运动感觉神经变性或受体功能障碍或不存在认知神经和神经损伤的情况下的治疗方法和用途。 神经肌肉损伤
-
公开(公告)号:US20120034193A1
公开(公告)日:2012-02-09
申请号:US13138251
申请日:2010-01-22
申请人: Daryl Rees , Antonia Orsi , Patrick Howson , Zongqin Xia , Yaer Hu
发明人: Daryl Rees , Antonia Orsi , Patrick Howson , Zongqin Xia , Yaer Hu
IPC分类号: A61K35/12 , C07J71/00 , A61P25/00 , A61P25/28 , A61P25/16 , A61P21/00 , A61P27/02 , A61P9/04 , A61P11/06 , A61P25/08 , A61P25/22 , A61P25/24 , A61P25/18 , A61P25/30 , A61P25/32 , A61P25/36 , A61P29/00 , A61P17/06 , A61P1/00 , A61P37/08 , A61P17/04 , A61P1/04 , A61P1/18 , A61P11/02 , A61P11/14 , A61P19/02 , A61P9/10 , A61P37/00 , A61P37/06 , A61P35/00 , A61P19/08 , A61P43/00 , A61K31/58
CPC分类号: A61K31/58 , A61K31/7048
摘要: An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.
摘要翻译: 使用选自A / B-顺式呋喃斯坦,呋喃葡萄烯,螺甾烷和螺甾烷基甾体皂苷元及其酯,醚,酮及其糖基化形式的药剂诱导神经营养因子(NF)的自我调节的体内平衡,例如BDNF和/或GDNF ,通过在稳态控制下以无毒的方式调节NF,在受试者中具有有限和易于治疗的副作用的NF。 特别是治疗或预防一系列NF介导的疾病,特别是神经系统疾病,精神病学,炎症,过敏性,免疫和肿瘤性疾病,以及在恢复或正常化过程中向受试者施用有效量的至少一种此类药剂 包括当辅助组织(例如皮肤,骨骼,眼睛和肌肉)愈合和一般皮肤,骨骼,眼睛和肌肉健康时,神经元和其他功能在任何损伤或异常组织中或与其相关。
-
公开(公告)号:US20080045591A1
公开(公告)日:2008-02-21
申请号:US11773952
申请日:2007-07-05
申请人: Daryl Rees , Phillip Gunning , Antonia Orsi , Patrick Howson , Paul Barraclough , Noelle Callizot
发明人: Daryl Rees , Phillip Gunning , Antonia Orsi , Patrick Howson , Paul Barraclough , Noelle Callizot
IPC分类号: A61K31/12 , A23L1/00 , A23L1/29 , A61P1/00 , A61P21/00 , A61P37/00 , C07C49/00 , C07C69/78 , C12N5/00 , C07C49/15 , A61P9/12 , A61P29/00 , A61P19/02 , A61K31/216 , A23L2/00
CPC分类号: A61K31/12 , C07C45/455 , C07C45/62 , C07C45/673 , C07C45/68 , C07C45/74 , C07C49/255 , C07C49/577 , C07C49/84 , C07C69/738 , C07C217/22 , C07C255/56 , C07C2601/02 , C07C2601/10 , C07C2601/14 , C07F7/1804 , Y02P20/582
摘要: Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cycloalkyl, optionally substituted C2-10alkenyl, and optionally substituted aryl; R4, R5 and R6 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, OH, optionally substituted C1-10 alkoxy, halo, optionally substituted aryloxy, optionally substituted (C1-10alkyl)-S(O)n— where n=0, 1 or 2, optionally substituted aryl-S(O)n— where n=0, 1 or 2, or R4 is hydrogen and R5 and R6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R1═R2=hydrogen, then any optionally substituted C1-10alkyl or optionally substituted C2-10alkenyl for R3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R3 is attached; or a physiologically acceptable salt, complex or prodrug thereof; are disclosed per se and for use in the treatment or prophylaxis of hypersensitivity, smooth muscle disorders, spasmodic conditions, allergic conditions, inflammatory conditions and/or pain.
-
公开(公告)号:US07589123B2
公开(公告)日:2009-09-15
申请号:US11773952
申请日:2007-07-05
申请人: Daryl David Rees , Phillip James Gunning , Antonia Orsi , Patrick A. Howson , Paul Barraclough , Noelle Callizot
发明人: Daryl David Rees , Phillip James Gunning , Antonia Orsi , Patrick A. Howson , Paul Barraclough , Noelle Callizot
CPC分类号: A61K31/12 , C07C45/455 , C07C45/62 , C07C45/673 , C07C45/68 , C07C45/74 , C07C49/255 , C07C49/577 , C07C49/84 , C07C69/738 , C07C217/22 , C07C255/56 , C07C2601/02 , C07C2601/10 , C07C2601/14 , C07F7/1804 , Y02P20/582
摘要: Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cycloalkyl, optionally substituted C2-10alkenyl, and optionally substituted aryl; R4, R5 and R6 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, OH, optionally substituted C1-10 alkoxy, halo, optionally substituted aryloxy, optionally substituted (C1-10alkyl)-S(O)n— where n=0, 1 or 2, optionally substituted aryl-S(O)n— where n=0, 1 or 2, or R4 is hydrogen and R5 and R6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R1═R2=hydrogen, then any optionally substituted C1-10alkyl or optionally substituted C2-10alkenyl for R3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R3 is attached; or a physiologically acceptable salt, complex or prodrug thereof; are disclosed per se and for use in the treatment or prophylaxis of hypersensitivity, smooth muscle disorders, spasmodic conditions, allergic conditions, inflammatory conditions and/or pain.
-
-
-
-